Histogenics (NSDQ:HSGX) said yesterday that it inked a definitive merger agreement with Ocugen through which both companies will combine into a single publicly-traded, clinical-stage biopharmaceutical company.
The combined entity will operate under the Ocugen name, the companies said. As part of the deal, Ocugen’s shareholders will become the majority owners of Histogenics outstanding common stock upon the closure of the merger.
Read the whole story on our sister site, Drug Delivery Business News
from MassDevice http://bit.ly/2UF529F
Cap comentari:
Publica un comentari a l'entrada